投資
204年投資退出
73年想告知投資者類似HBM醫療投資關於你的公司嗎?
提交你的分析師簡報在投資者麵前,CB Insights的平台上的客戶和合作夥伴。188bet游戏
最新的HBM醫療投資新聞
2023年7月21日
21 - 7 - 2023 / 06:30 CET(中央東部東京)/ c發行人單獨負責這個聲明的內容。減少每股資產淨值(NAV) 0.6%的季度審查由於不利的貨幣發展盡管抑製了市場環境,有吸引力的出口仍有可能,以幾家投資公司投資組合仍遠平衡和價值創造潛力的完整的季度結果推到紅HBM不利的貨幣發展醫療保健投資關閉2023/2024財年第一季度在2023年6月30日1100萬瑞士法郎的損失。每股資產淨值(NAV)在此期間下降了0.6%,而股價下跌了5.6%。投資貨幣,投資組合記錄一個積極的結果在截至2023年6月30日的三個月。然而,不利的貨幣兌瑞郎發展(美元-2.2%,人民幣和歐元-1.5% -7.3%)資產淨值減少了3.2%的總報告季度導致一個小整體損失。私營企業的投資組合的發展私營企業負擔的季度結果與淨600萬瑞士法郎。這包括消極的貨幣發展1300萬瑞士法郎。以下事件引人注目:上遊生物籌集了2億美元的新資本。HBM醫療投資參與這個融資共有1000萬美元的部分。由於人民幣升值,現有投資的價值增加了1200萬瑞士法郎。 Further value adjustments due to completed or pending financing rounds were made at 1000Farmacie (CHF +2.4 million), Farmalatam (CHF -6.9 million) and Fore Biotherapeutics (CHF -2.4 million). Developments in the portfolio of public companies The value of public companies increased by CHF 9 million net, even though currency developments burdened the quarterly result with CHF 37 million. Cathay Biotech, the largest position, announced a strategic collaboration with China Merchants Group (CMG) which will invest up to RMB 6.6 billion (approx. CHF 800 million) in the company. Furthermore, CMG commits to purchasing large quantities of bio-based polyamides from Cathay and cooperate in the area of research and development. Although Cathay's share price increased slightly in the quarter under review, the negative currency development resulted in an overall net value reduction of just under CHF 17 million. Prometheus Biosciences was acquired by Merck & Co. in April for USD 11 billion. Prometheus develops therapies to treat the inflammatory bowel diseases ulcerative colitis and Crohn's disease. Moreover, Chinook Therapeutics agreed to a USD 3.5 billion takeover bid by Novartis in June. Chinook develops therapies for chronic kidney disease. The two acquisitions resulted in a total profit contribution of CHF 11 million. Developments in the fund portfolio The fund portfolio burdened the result in the quarter under review by about CHF 6 million, CHF 4 million of which was due to currency developments. Asset allocation The portfolio remains well balanced with public companies accounting for 44 percent of consolidated assets (of which 26 percent were formerly private companies), 35 percent private companies, 9 percent funds and 12 percent cash and cash equivalents as well as other assets. Outlook The market environment remains dominated by investor concerns about inflation, rising interest rates and a cooling economy. Currency developments also continued to create headwinds at the beginning of the quarter. For the portfolio companies, however, this challenging financing environment also offers opportunities. As the examples of Upstream Bio, Prometheus Biosciences and Chinook Therapeutics demonstrate, companies with convincing research results benefit from high demand and attractive offers in financing rounds and acquisition bids. With the aforementioned strategic agreement with CMG, Cathay Biotech has laid a solid foundation for further growth. In addition, the loc Overall, with a carefully selected portfolio and a solid balance sheet, HBM Healthcare Investments remains ideally positioned to take advantage of opportunities and benefit from positive market momentum. The Quarterly Report June 2023 is available on the Company’s website www.hbmhealthcare.com/en/investors/financial-reports. Contact For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com. End of Inside Information
HBM醫療投資的投資
204年投資
HBM醫療投資了204年投資。他們最新的投資上遊生物作為他們的一部分B係列在2023年6月6日。
HBM醫療投資的投資活動
日期 |
輪 |
公司 |
量 |
新的嗎? |
共同投資者 |
來源 |
---|---|---|---|---|---|---|
6/8/2023 |
B係列 |
上遊生物 |
200美元 |
沒有 |
5 |
|
12/29/2022 |
B係列 |
ArriVent生物製藥 |
155美元 |
是的 |
5 |
|
11/21/2022 |
D係列 |
FogPharma |
178美元 |
沒有 |
16 |
|
10/13/2022 |
B係列 |
|||||
9/6/2022 |
Unattributed VC |
日期 |
6/8/2023 |
12/29/2022 |
11/21/2022 |
10/13/2022 |
9/6/2022 |
---|---|---|---|---|---|
輪 |
B係列 |
B係列 |
D係列 |
B係列 |
Unattributed VC |
公司 |
上遊生物 |
ArriVent生物製藥 |
FogPharma |
||
量 |
200美元 |
155美元 |
178美元 |
||
新的嗎? |
沒有 |
是的 |
沒有 |
||
共同投資者 |
|||||
來源 |
5 |
5 |
16 |
HBM醫療投資投資退出
73年投資退出
HBM醫療投資有73年投資組合出口。他們最新的投資退出Mineralys療法 在2023年2月10日。
日期 |
退出 |
公司 |
估值
提交的估值公司,采自國家申請或者新聞,由VentureSource的提供,或基於比較數據的估值模型。
|
收購者 |
來源 |
---|---|---|---|---|---|
2/10/2023 |
首次公開募股 |
公共 |
5 |
||
12/14/2022 |
收購了 |
2 |
|||
11/15/2022 |
首次公開募股 |
公共 |
3 |
||
日期 |
2/10/2023 |
12/14/2022 |
11/15/2022 |
||
---|---|---|---|---|---|
退出 |
首次公開募股 |
收購了 |
首次公開募股 |
||
公司 |
|||||
估值 |
|||||
收購者 |
公共 |
公共 |
|||
來源 |
5 |
2 |
3 |
HBM醫療投資團隊
2團隊成員
HBM醫療投資有2 團隊成員,包括現任首席執行官安德烈亞斯Wicki。
的名字 |
工作經曆 |
標題 |
狀態 |
---|---|---|---|
Andreas Wicki |
|
首席執行官 |
當前的 |
的名字 |
Andreas Wicki |
|
---|---|---|
工作經曆 |
|
|
標題 |
首席執行官 |
|
狀態 |
當前的 |
發現正確的解決方案為您的團隊
CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。